LexisNexis® CLE On-Demand features premium content from partners like American Law Institute Continuing Legal Education and Pozner & Dodd. Choose from a broad listing of topics suited for law firms, corporate legal departments, and government entities. Individual courses and subscriptions available.
By Mary B. Langowski and Kristen E. Ratcliff A little more than five years after the passage of the Health Information Technology Economic and Clinical Health (HITECH) Act, the Food and Drug Administration, Federal Communications Commission and the Office of the National Coordinator for Health IT have released a draft report outlining a proposed strategy and recommendations for a “risk based” regulatory framework for health information technology. The draft report was released amidst stakeholder calls for additional clarity on how the federal government will regulate the health IT industry – an industry that has seen significant growth in recent years due to the incentives for adoption and use of electronic health records offered under the HITECH Act, as well as the use of technology to support emerging payment and delivery models. This draft report is likely one in a series of guidance documents and regulations that will shape the federal government’s footprint in this space over the years to come. It outlines a number of opportunities for private sector stakeholders to engage with the agencies as they continue to shape their policies and thinking in this space and may also inform subsequent legislative efforts. See our brief overview of the draft report.
Published by DLA Piper LLP (US)Copyright © 2014 DLA Piper LLP (US)All Rights Reserved This bulletin is intended as a general overview and discussion of the subjects dealt with. It is not intended, and should not be used, as a substitute for taking legal advice in any specific situation. DLA Piper will accept no responsibility for any actions taken or not taken on the basis of this publication. Pursuant to applicable Rules of Professional Conduct, it may constitute advertising. Circular 230 Notice: In compliance with US Treasury Regulations, please be advised that any tax advice given herein (or in any attachment) was not intended or written to be used, and cannot be used, for the purpose of (i) avoiding tax penalties or (ii) promoting, marketing or recommending to another person any transaction or matter addressed herein. You are receiving this communication because you are a valued client or friend of DLA Piper. DLA Piper LLP (US) is part of DLA Piper, a global law firm, operating through various separate and distinct legal entities. Further details of these entities can be found at www.dlapiper.com. All rights reserved. To unsubscribe from this mailing list, reply to this message with REMOVE in the subject line.
For more information about LexisNexis products and solutions, connect with us through our corporate site.